Chimeric Antigen Receptor (CAR) T Cell Immunotherapy

Most Exhaustive Report

Chimeric Antigen Receptor (CAR) T Cell Immunotherapy - Pipeline Insights 2018

20% Discount If you buy now
Chimeric Antigen Receptor (CAR) T Cell Immunotherapy

Most Exhaustive Report

Chimeric Antigen Receptor (CAR) T Cell Immunotherapy - Pipeline Insights 2018

SKU : APA17804 Published on : February 2018 Pages : 70

${{licencetype}} 20% Discount

20% Discount on this report. Ends in

Get 10% Free Customization
On This Report.
Customize this report Enquire before buying
data center market research

Get actionable insights on how COVID-19 is impacting your business sector.

Enquire now

CAR-T cell immunotherapy

CAR-T cell immunotherapy represents one of a major breakthrough in cancer research. For decades, the cornerstones of cancer treatment have been chemotherapy, surgery, and radiation therapy. Over the past decade, targeted therapies and immunotherapies have changed cancer treatment paradigm. The CAR-T cell therapy, a form of immunotherapy, is a novel adoptive antitumor treatment. Ideally, CAR-T cells can particularly localize and destroy tumor cells by interacting with the tumor specific antigens located on tumor cell surface.

CAR-T cell therapy showed promising results in the treatment of haematological malignancies and solid tumors. The third generation of CAR-T cell therapy demonstrates increased antitumor cytotoxicity and persistence through modifying the structureof CAR-T cells. In this report, we mentioned the preclinical and clinical progress of CAR-T cells targeting various variants including EGFR, human epidermal growth factor receptor 2 (HER2), and mesothelin (MSLN).

The manufacturing of CD19 CAR T cell immunotherapy CTL019 is in a way which will reform the process of using the CAR T cell therapy globally. The anticipation of regulatory and manufacturing challenges before they rise and proactively addressing the disquiets helps to hasten the process of bringing this promising novel approach to more patients in future. Few of other promising CAR T cell candidates currently in the pipeline are KTE-C19, JCAR020, JCAR 024, JCAR015, JCAR017, UCART19, S68587, UCART123, MB-101, bb2121, PCAR-119, anti-CD19 CAR-NK cells, MB-102, AU-101, huCART19, huCTL019, BPX-401 (CIDeCAR), OXB-302, ICG-122, CD4CAR, ICG-124, CD5CAR, ICG-142, ICG-140, ICG-138/ICG-139, ICG-136. Few of the key companies which are involved in the development of CAR-T cell therapy include Amgen, CARsgen, Celgene, Cellectis, Humorigin, iCell Gene, Innovative Cellular Therapeutics, Intellia Therapeutics, Intrexon, J&J, Kite Pharma, MabVax, MaxCyte, Novartis, Oncternal, Opus Bio, Pfizer, Sorrento, Takara and Ziopharm.

Reasons to Buy

  • To gain erudite insights about the Chimeric Antigen Receptor (CAR) T cell immunotherapypipeline landscape
  • To ascertain unique product development dynamics and leverage it for new target identification, drug repositioning, and precision medicine
  • To optimize the pipeline product portfolio in correspondence with the dynamic pharmaceutical market
  • To identify competitors and design strategic initiatives for drug development activities
  • To understand the market and choose right partners for strategic collaborations
  • To obtain informed updates on drug termination/drug discontinuation


Client Speak

data center market size

Erik Young

CEO, Co-founder
Audink Inc., DBA Audios

The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow.

data center market

Benjamin Arnold

Senior Product Manager

I recently purchased a key Arizton Industry Outlook & Forecast in order to better understand growth for specific market segments and the macro environmental factors impacting this growth. I found Arizton’s coverage of the market dynamics and key takeaways to be insightful and valuable. The segmentation breakouts gave me the information I needed to guide strategic considerations.

data center market research

Hallmann, Nickolai

Manager Market Analyst Power
Generation & Energy
Rolls-Royce Power Systems AG

The provided information by Arizton really met my expectations. Especially the deep information about the datacenter ecosystem was very helpful. Furthermore, I absolutely appreciate the optimal service from the key account managers of Arizton. It was always a pleasure working with them.

Customer Service



Copyright 2019 - Arizton

data center market